This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Gastro-oesophageal reflux and cisapride

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Cisapride was more effective than placebo in diminishing symptoms and endoscopically-visible lesions associated with reflux oesophagitis.

Cisapride and cimetidine seemed to offer an additive benefit.

Maintenance doses halve the relapse rate of mild reflux compared to placebo.

The recommended doses of cisapride for reflux were:

  • for symptoms and mucosal lesions, 10mg tds or qds; or 20mg bd PO
  • for maintenance treatment, 20mg nocte or 10mg bd

A twelve week course was recommended.

This drug was withdrawn from marketing in the UK from 28th July 2000 until further notice. This is because cisapride can prolong the QT interval, which may lead to rare but life-threatening ventricular arrythmias. The committee on Safety of Medicines has advised that all treatment with cisapride should be stopped and patients should be changed to an alternative treatment as necessary.

Reference:

  • 1) Committee on Safety of Medicines (July 2000).Suspension of cisapride (Prepulsid): Product withdrawal.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.